ImmuPharma

About:

ImmuPharma plc is a United Kingdom-based drug discovery and development company. The Company is focused on developing drugs.

Website: http://www.immupharma.co.uk/

Twitter/X: immupharma

Top Investors: Lanstead Capital

Description:

ImmuPharma focuses in developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry. Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value at a relatively low cost, and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.

Total Funding Amount:

$12.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Westminster, Westminster, United Kingdom

Founded Date:

1999-01-01

Contact Email:

info(AT)immupharma.com

Founders:

Dimitri F Dimitriou, Gilles Guichard, Jean-Paul Briand

Number of Employees:

11-50

Last Funding Date:

2016-02-10

IPO Status:

Public

Industries:

© 2025 bioDAO.ai